
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell is showing strong potential for growth in the near future, with a significant increase in usage expected for their delirium monitoring product following FDA clearance. The company has a wide range of hospital settings where their products are being used, and the addition of a pediatric/neonate offering is expected to further expand their revenue. With a clean execution, strong financials, and a healthy business model, CeriBell is a solid investment option for the future.
Bears say
CeriBell is poised for growth with a strong market position in point-of-care rapid EEG and plans for label expansions. However, potential risks such as geopolitical tensions, competition, and regulatory decisions could impact its growth potential. The company has also recently received FDA 510(k) approval for two new AI algorithm enhancements and announced the development of a new hardware platform, potentially increasing its appeal and market share. While the stock may have near-term volatility, the company's long-term outlook is positive, with an expected increase in account adds and overall utilization.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares